MedTrace Logo

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

NCT01259869 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-08-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.

Conditions

Interventions

DRUG

PX-866

1 cycle = 8 weeks on study PX-866 - 8mg PO Daily

Sponsors & Collaborators

  • Cascadian Therapeutics Inc.

    collaborator INDUSTRY

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Marshall Pitz · CancerCare Manitoba

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-01
Primary Completion
2014-10-29
Completion
2015-02-13
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01259869 on ClinicalTrials.gov